Axsome Therapeutics announced a 57% year-over-year increase in net product revenue to $191.2 million for Q1 2026, driven by strong sales of AUVELITY and SUNOSI. AUVELITY, approved by the FDA for agitation in Alzheimer’s disease, saw 59% revenue growth and is set for a full commercial launch in June 2026. The company also submitted an NDA for AXS-12 for narcolepsy and added a new drug candidate for schizophrenia and Tourette syndrome to its pipeline. Axsome plans to expand its sales force and advance multiple late-stage clinical trials, aiming to address significant unmet needs in CNS disorders.
Moment Factory and Mitsui Fudosan have formed a long-term strategic partnership to develop large-scale immersive fan experiences, including a new Pokémon attraction set to launch in Europe in spring 2027. This collaboration combines Moment Factory's ...
FCCE, the majority shareholder of Installux, has agreed to acquire 6.38% of Installux shares from Amiral Gestion at €500 per share, totaling €8.93 million. Following this acquisition, FCCE will hold 87.45% of Installux's capital and voting rights. FC...
Toll Brothers announced a new luxury home community called Toll Brothers at West Park in Ashburn, Virginia, located in the Brambleton neighborhood. The community will feature modern single-family homes with 3 to 5 bedrooms, up to 3,300 square feet, a...
The Nasdaq 100 index surpassed 30,000 points during Tuesday's session, led by a strong rally in semiconductor stocks, especially Micron Technology which surged 18%. This rally was fueled by rising expectations for AI-related spending, with UBS raisin...
Hyliion's stock surged to a 52-week high following its partnership with the U.S. Navy to test its KARNO power system on an autonomous naval vessel. The company reported better-than-expected Q1 results, with revenue of $2.83 million and a smaller loss...
